Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) EBITDA (2020 - 2026)

Climb Bio filings provide 7 years of EBITDA readings, the most recent being -$14.0 million for Q1 2026.

  • Quarterly EBITDA rose 31.77% to -$14.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$52.9 million through Mar 2026, up 42.91% year-over-year, with the annual reading at -$59.4 million for FY2025, 19.54% up from the prior year.
  • EBITDA hit -$14.0 million in Q1 2026 for Climb Bio, up from -$17.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.7 million in Q1 2024 and bottomed at -$54.9 million in Q2 2024.
  • Average EBITDA over 5 years is -$13.4 million, with a median of -$9.7 million recorded in 2022.
  • The largest annual shift saw EBITDA skyrocketed 92.3% in 2024 before it plummeted 1110.5% in 2025.
  • Climb Bio's EBITDA stood at -$7.5 million in 2022, then surged by 51.82% to -$3.6 million in 2023, then plummeted by 136.62% to -$8.6 million in 2024, then tumbled by 104.21% to -$17.6 million in 2025, then grew by 20.23% to -$14.0 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's EBITDA are -$14.0 million (Q1 2026), -$17.6 million (Q4 2025), and -$12.7 million (Q3 2025).